158 related articles for article (PubMed ID: 37351997)
21. Chemokine receptor CCR7 expression predicts poor outcome in uveal melanoma and relates to liver metastasis whereas expression of CXCR4 is not of clinical relevance.
van den Bosch T; Koopmans AE; Vaarwater J; van den Berg M; de Klein A; Verdijk RM
Invest Ophthalmol Vis Sci; 2013 Nov; 54(12):7354-61. PubMed ID: 24052640
[TBL] [Abstract][Full Text] [Related]
22. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment.
Obermajer N; Muthuswamy R; Odunsi K; Edwards RP; Kalinski P
Cancer Res; 2011 Dec; 71(24):7463-70. PubMed ID: 22025564
[TBL] [Abstract][Full Text] [Related]
23. CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer.
Zheng N; Liu W; Chen J; Li B; Liu J; Wang J; Gao Y; Shao J; Jia L
Mol Carcinog; 2019 Jan; 58(1):144-155. PubMed ID: 30259564
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells.
Chen G; Chen SM; Wang X; Ding XF; Ding J; Meng LH
J Biol Chem; 2012 Apr; 287(15):12132-41. PubMed ID: 22337890
[TBL] [Abstract][Full Text] [Related]
25. The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow.
Shakir M; Tang D; Zeh HJ; Tang SW; Anderson CJ; Bahary N; Lotze MT
Pancreas; 2015 May; 44(4):528-34. PubMed ID: 25872129
[TBL] [Abstract][Full Text] [Related]
26. The prognostic significance and impact of the CXCR4-CXCR7-CXCL12 axis in primary cutaneous melanoma.
McConnell AT; Ellis R; Pathy B; Plummer R; Lovat PE; O'Boyle G
Br J Dermatol; 2016 Dec; 175(6):1210-1220. PubMed ID: 27167239
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic changes of CXCR4 and its ligand CXCL12 as prognostic factors for sporadic breast cancer.
Ramos EA; Grochoski M; Braun-Prado K; Seniski GG; Cavalli IJ; Ribeiro EM; Camargo AA; Costa FF; Klassen G
PLoS One; 2011; 6(12):e29461. PubMed ID: 22220212
[TBL] [Abstract][Full Text] [Related]
28. Endocrine disrupting chemicals promote the growth of ovarian cancer cells via the ER-CXCL12-CXCR4 signaling axis.
Hall JM; Korach KS
Mol Carcinog; 2013 Sep; 52(9):715-25. PubMed ID: 22549810
[TBL] [Abstract][Full Text] [Related]
29. Notch pathway promotes ovarian cancer growth and migration via CXCR4/SDF1α chemokine system.
Chiaramonte R; Colombo M; Bulfamante G; Falleni M; Tosi D; Garavelli S; De Simone D; Vigolo E; Todoerti K; Neri A; Platonova N
Int J Biochem Cell Biol; 2015 Sep; 66():134-40. PubMed ID: 26235278
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of CXCL12 and CXCR4 in inoperable head and neck squamous cell carcinoma.
Rave-Fränk M; Tehrany N; Kitz J; Leu M; Weber HE; Burfeind P; Schliephake H; Canis M; Beissbarth T; Reichardt HM; Wolff HA
Strahlenther Onkol; 2016 Jan; 192(1):47-54. PubMed ID: 26374452
[TBL] [Abstract][Full Text] [Related]
31. Blockade of CXCL12/CXCR4 signaling inhibits intrahepatic cholangiocarcinoma progression and metastasis via inactivation of canonical Wnt pathway.
Zhao S; Wang J; Qin C
J Exp Clin Cancer Res; 2014 Dec; 33(1):103. PubMed ID: 25471741
[TBL] [Abstract][Full Text] [Related]
32. Abortifacient metapristone (RU486 derivative) interrupts CXCL12/CXCR4 axis for ovarian metastatic chemoprevention.
Zheng N; Chen J; Li T; Liu W; Liu J; Chen H; Wang J; Jia L
Mol Carcinog; 2017 Aug; 56(8):1896-1908. PubMed ID: 28277622
[TBL] [Abstract][Full Text] [Related]
33. [Effects of chemokine receptor and its ligand on migration of ovarian cancer cells].
Li F; Zhu HS; Han ZQ; Chen G; Gao QL; Jia P; Zhang AL; Xi L; Xu Q; Liao GN; Wang SX; Lu YP; Ma D
Ai Zheng; 2005 Jan; 24(1):23-7. PubMed ID: 15642195
[TBL] [Abstract][Full Text] [Related]
34. CXCL12/CXCR4 promotes proliferation, migration, and invasion of adamantinomatous craniopharyngiomas via PI3K/AKT signal pathway.
Yin X; Liu Z; Zhu P; Wang Y; Ren Q; Chen H; Xu J
J Cell Biochem; 2019 Jun; 120(6):9724-9736. PubMed ID: 30582214
[TBL] [Abstract][Full Text] [Related]
35. CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR.
Circelli L; Sciammarella C; Guadagno E; Tafuto S; del Basso de Caro M; Botti G; Pezzullo L; Aria M; Ramundo V; Tatangelo F; Losito NS; Ieranò C; D'Alterio C; Izzo F; Ciliberto G; Colao A; Faggiano A; Scala S
Oncotarget; 2016 Apr; 7(14):18865-75. PubMed ID: 26934559
[TBL] [Abstract][Full Text] [Related]
36. Chemokine receptor CXCR4 and its ligand CXCL12 expressions and clinical significance in bladder cancer.
Yang DL; Xin MM; Wang JS; Xu HY; Huo Q; Tang ZR; Wang HF
Genet Mol Res; 2015 Dec; 14(4):17699-707. PubMed ID: 26782415
[TBL] [Abstract][Full Text] [Related]
37. CD164 regulates the tumorigenesis of ovarian surface epithelial cells through the SDF-1α/CXCR4 axis.
Huang AF; Chen MW; Huang SM; Kao CL; Lai HC; Chan JY
Mol Cancer; 2013 Oct; 12(1):115. PubMed ID: 24094005
[TBL] [Abstract][Full Text] [Related]
38. CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of disease-free and overall survival.
Mirisola V; Zuccarino A; Bachmeier BE; Sormani MP; Falter J; Nerlich A; Pfeffer U
Eur J Cancer; 2009 Sep; 45(14):2579-87. PubMed ID: 19646861
[TBL] [Abstract][Full Text] [Related]
39. CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies.
Khare T; Bissonnette M; Khare S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298991
[TBL] [Abstract][Full Text] [Related]
40. Expression of angiogenic chemokines in ovarian clear cell carcinoma.
Quattrocchi L; Sisson M; Green A; Martin SG; Durrant L; Deen S
J Obstet Gynaecol Res; 2013 Jan; 39(1):297-304. PubMed ID: 22845872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
